Precting Brain Amyloidosis With Plasma ?-Amyloid42/40 and MRI-Based Morphometry Features

Biomarker assisting early detection and intervention in Alzheimer’s disease (AD) may be the key to therapeutic breakthroughs. One of the presymptomatic hallmarks of AD is the accumulation of beta-amyloid (Aβ) plaques in the human brain. However, current methods to detect brain Aβ pathology are either invasive (lumbar puncture) or quite costly and not widely available (amyloid PET). The blood-based biomarker, like plasma Aβ42/Aβ40, enables more rapid and inexpensive screening of potential participants for brain amyloidosis [1]. Additionally, our recent research has demonstrated that MRI-based hippocampal multivariate morphometry statistics (MMS) can be an effective neurodegenerative biomarker for predicting brain amyloid deposition [2]. In this study, we demonstrate that the combination of these two state-of-the-art biomarkers could achieve superior performance in predicting the brain Aβ burden assessed based on amyloid PET.